Not Yet RecruitingNot Applicable

Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)

United States85 participantsStarted 2026-07-01

Plain-language summary

The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underreported complication of Allogeneic Stem Cell Transplant (SCT). The main question it aims to answer is: What is the incidence of TA-TMA in adults undergoing SCT? How does TA-TMA diagnosis impact survival and other outcomes? Patients undergoing SCT will be eligible for this study, which will consist of collection of biological samples and standard clinical follow up.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult male or female, age ≥18
✓. Undergoing allogeneic SCT at UAB for any indication and any donor source.
✓. For patients in cohort 1: Patients deemed high-risk for developing high-risk TA-TMA as stated by any of the following criteria\*:
✓. BMI \> 35\[42\]
✓. Mismatched donor (either Haploidentical or Mismatched Unrelated donor)\[18, 29\]
✓. Non-Malignant Transplant Indication (Severe Aplastic Anemia or Sickle Cell Disease)\[18, 43\]
✓. Acute Lymphoblastic Leukemia (any kind)\[18, 31\]
✓. African American, Hispanic, Asian or Native American Ethnicity \[44\]

Exclusion criteria

✕. Any other active malignancy requiring treatment or with expected survival ≤1 year.
✕. Patients with psychiatric illness or social situations that would limit compliance with the study requirements.

What they're measuring

Primary Objectives

Timeframe: From enrollment until 1 year post SCT

Co-Primary Objective

Timeframe: From enrollment until 1 year post SCT

Trial details

NCT IDNCT07381205

SponsorManuel Ricardo Espinoza-Gutarra

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-10

Contact for this trial

Manuel R Espinoza Gutarra, M.D.

205-975-2576 mgutarra@uabmc.edu

View on ClinicalTrials.gov More Transplant Associated Microangiopathy TAM trials